At 3 months, findings showed 80.4% of patients treated with Juvéderm Voluma XC achieved at least a 1-point improvement in moderate to severe temple hollowing. The Food and Drug Administration (FDA) ...
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...
JUVÉDERM® VOLUX™ XC IS THE FIRST AND ONLY HYALURONIC ACID (HA) FILLER TO RECEIVE U.S. FDA APPROVAL FOR IMPROVING JAWLINE DEFINITION IRVINE, Calif., Aug. 3, 2022 /PRNewswire/ -- Today, Allergan ...
Juvéderm Volux XC is an injectable gel filler containing hyaluronic acid. The Food and Drug Administration (FDA) has approved Juvéderm ® Volux ™ XC for the improvement of jawline definition in ...
IRVINE, Calif., Aug. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the first ever JUVÉDERM® Day on Wednesday, August 16, 2023. The celebration recognizes the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results